157 related articles for article (PubMed ID: 35642433)
1. Neoadjuvant chemoimmunotherapy in early triple-negative breast cancer: a new kid on the block?
Rizzo A; Palmiotti G
Immunotherapy; 2022 Jul; 14(10):755-758. PubMed ID: 35642433
[No Abstract] [Full Text] [Related]
2. Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward.
Rizzo A; Cusmai A; Gadaleta-Caldarola G; Palmiotti G
Medicina (Kaunas); 2022 Apr; 58(5):. PubMed ID: 35630016
[TBL] [Abstract][Full Text] [Related]
3. Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis.
Rizzo A; Cusmai A; Massafra R; Bove S; Comes MC; Fanizzi A; Rinaldi L; Acquafredda S; Gadaleta-Caldarola G; Oreste D; Zito A; Giotta F; Lorusso V; Palmiotti G
Cells; 2022 Jun; 11(12):. PubMed ID: 35740985
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials.
Tarantino P; Gandini S; Trapani D; Criscitiello C; Curigliano G
Crit Rev Oncol Hematol; 2021 Mar; 159():103223. PubMed ID: 33482345
[TBL] [Abstract][Full Text] [Related]
5. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
Schmid P; Cortes J; Dent R; Pusztai L; McArthur H; Kümmel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Untch M; Fasching PA; Cardoso F; Andersen J; Patt D; Danso M; Ferreira M; Mouret-Reynier MA; Im SA; Ahn JH; Gion M; Baron-Hay S; Boileau JF; Ding Y; Tryfonidis K; Aktan G; Karantza V; O'Shaughnessy J;
N Engl J Med; 2022 Feb; 386(6):556-567. PubMed ID: 35139274
[TBL] [Abstract][Full Text] [Related]
6. Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis.
Latif F; Bint Abdul Jabbar H; Malik H; Sadaf H; Sarfraz A; Sarfraz Z; Cherrez-Ojeda I
Expert Rev Anticancer Ther; 2022 Feb; 22(2):229-235. PubMed ID: 34949142
[TBL] [Abstract][Full Text] [Related]
7. Letter to the Editor Regarding "Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single Agent Pembrolizumab for High-Risk Early-Stage Triple Negative Breast Cancer in the United States".
Sorscher S
Adv Ther; 2023 Sep; 40(9):4111-4113. PubMed ID: 37432550
[No Abstract] [Full Text] [Related]
8. [New drug approval: Pembrolizumab - Neoadjuvant/adjuvant treatment for localized high-risk triple negative breast cancer].
Minot-This MS; Deleuze A
Bull Cancer; 2022 Oct; 109(10):988-989. PubMed ID: 35871860
[No Abstract] [Full Text] [Related]
9. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Cortes J; Cescon DW; Rugo HS; Nowecki Z; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Holgado E; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Guo Z; Zhao J; Aktan G; Karantza V; Schmid P;
Lancet; 2020 Dec; 396(10265):1817-1828. PubMed ID: 33278935
[TBL] [Abstract][Full Text] [Related]
10. Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature.
Feng D; Guan Y; Liu M; He S; Zhao W; Yin B; Liang J; Li Y; Wang J
Front Immunol; 2021; 12():608292. PubMed ID: 34135884
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study.
Schmid P; Salgado R; Park YH; Muñoz-Couselo E; Kim SB; Sohn J; Im SA; Foukakis T; Kuemmel S; Dent R; Yin L; Wang A; Tryfonidis K; Karantza V; Cortés J; Loi S
Ann Oncol; 2020 May; 31(5):569-581. PubMed ID: 32278621
[TBL] [Abstract][Full Text] [Related]
12. Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer.
Chun B; Pucilowska J; Chang S; Kim I; Nikitin B; Koguchi Y; Redmond WL; Bernard B; Rajamanickam V; Polaske N; Fields PA; Conrad V; Schmidt M; Urba WJ; Conlin AK; McArthur HL; Page DB
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086949
[TBL] [Abstract][Full Text] [Related]
13. [Pembrolizumab plus chemotherapy combination - first line in PD-L1 positive (CPS≥10) metastatic and advanced triple-negative breast cancer].
Loison R; Loirat D
Bull Cancer; 2022 Apr; 109(4):387-389. PubMed ID: 35256159
[No Abstract] [Full Text] [Related]
14. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
Mittendorf EA; Zhang H; Barrios CH; Saji S; Jung KH; Hegg R; Koehler A; Sohn J; Iwata H; Telli ML; Ferrario C; Punie K; Penault-Llorca F; Patel S; Duc AN; Liste-Hermoso M; Maiya V; Molinero L; Chui SY; Harbeck N
Lancet; 2020 Oct; 396(10257):1090-1100. PubMed ID: 32966830
[TBL] [Abstract][Full Text] [Related]
15. Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences?
Bonadio RC; Tarantino P; Testa L; Punie K; Pernas S; Barrios C; Curigliano G; Tolaney SM; Barroso-Sousa R
Cancer Treat Rev; 2022 Nov; 110():102459. PubMed ID: 35998514
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of pembrolizumab based therapies in triple-negative breast cancer: A systematic review of clinical trials.
Ali MA; Aiman W; Shah SS; Hussain M; Kashyap R
Crit Rev Oncol Hematol; 2021 Jan; 157():103197. PubMed ID: 33309890
[TBL] [Abstract][Full Text] [Related]
17. Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer.
Wang H; Ma H; Sové RJ; Emens LA; Popel AS
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579739
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab in the preoperative setting of triple-negative breast cancer: safety and efficacy.
Barroso-Sousa R; Tolaney SM
Expert Rev Anticancer Ther; 2020 Nov; 20(11):923-930. PubMed ID: 32930616
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy in Triple-Negative Breast Cancer.
Emens LA
Cancer J; 2021 Jan-Feb 01; 27(1):59-66. PubMed ID: 33475294
[TBL] [Abstract][Full Text] [Related]
20. KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer.
Rizzo A; Cusmai A; Acquafredda S; Giovannelli F; Rinaldi L; Misino A; Palmiotti G
Future Oncol; 2022 Jun; 18(18):2301-2309. PubMed ID: 35378995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
